Is Covista’s Expanded Advocate Health Nursing Pathway Reshaping the Long-Term Education Thesis For CVSA?

• In June 2026, Covista’s Chamberlain University and Advocate Health announced a collaboration to expand access to nursing education, offering scholarships, clinical experience at Advocate Health facilities, and loan repayment support to create a structured path into the profession.
• The partnership’s specialized Acute and Progressive Care nursing pathway, designed to produce practice-ready nurses at scale, directly targets growing clinical staffing needs across Advocate Health’s communities.
• We’ll now examine how this expanded, practice-ready nursing pipeline through Advocate Health could influence Covista’s longer-term education-focused investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Covista Investment Narrative Recap

To own Covista, you need to believe its health care focused education model can keep attracting students and converting that demand into solid cash generation. The Advocate Health partnership slightly strengthens the near term catalyst of improving Chamberlain enrollment by offering a clearer, funded path into nursing, but it does not remove the key risk that sustained softness in Chamberlain’s total enrollment and margins could still weigh on consolidated earnings.

Among recent updates, the May 2026 guidance raise to US$1.93 billion to US$1.945 billion in revenue is most relevant here, because it shows management’s confidence in near term demand while Chamberlain works through flat to soft enrollment. The Advocate Health pathway fits into that backdrop as one more enrollment funnel, but investors still need to watch how those initiatives translate into actual utilization and profitability across nursing programs.

Yet even with these positives, there is still meaningful risk around whether Chamberlain’s paused enrollment can return to growth and investors should be aware of...

Read the full narrative on Covista (it's free!)

Covista's narrative projects $2.3 billion revenue and $348.8 million earnings by 2029. This requires 7.0% yearly revenue growth and a $94.8 million earnings increase from $254.0 million today.

Uncover how Covista's forecasts yield a $153.25 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Covista could reach about US$2.3 billion in revenue and around US$380.6 million in earnings by 2029, so if you see this new Advocate Health pipeline as reinforcing those aggressive growth and margin assumptions, it is worth remembering that others worry the current pause in Chamberlain enrollment could persist, which shows how far apart views on the same news can be.

Explore 3 other fair value estimates on Covista - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Covista research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Covista research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Covista's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com